Novo Nordisk Archives

Screenshot 2016 11 01 at 3.27.32 PM e1478010517232

News and Trends 1 Nov 2016

Novo Nordisk pressured into Dropping Needle-Free Oral Insulin

Needle-free diabetes will have to wait: payers are pressuring pharma to provide lower medication prices, and Novo Nordisk has responded by redirecting its R&D strategy into more innovative research. Despite its position as a world leader in diabetes, Novo Nordisk seems to be hitting a rough patch: the big pharma is reducing its profit and […]

November 1, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Sep 2016

Denmark: The ‘Best CEO of the World’ to retire at Year’s End

The CEO of Novo Nordisk, who was named ‘Best CEO in the World’ by the Harvard Business Review in October 2015, will not have a chance to dominate the ranking again next year. He will retire by the end of the year (and have some well-deserved holidays). Lars Sorensen, or rather, Sørensen, joined the world-leading producer […]

September 6, 2016 - 2 minutesmins - By Philip Hemme

sanofi novo nordisk diabetes insulin glp 1 agonist combination

News and Trends 22 Aug 2016

Sanofi loses lead on new Diabetes drug, because of… an user-unfriendly Pen

Sanofi and Novo Nordisk have been in a tight race to put their new insulin GLP-1 combination drugs for Type 2 Diabetes on the market. Sanofi now suffers a short (but critical) setback, as the FDA is not impressed with its drug delivery system. Sanofi and Novo Nordisk have both strong positions in the diabetes […]

August 22, 2016 - 3 minutesmins - By Denise Neves Gameiro

diabetes glucose chronic disease biotech pharma review

News and Trends 14 Jun 2016

Could this be the ‘Beginning of the end’ for Diabetes? Let’s Review.

Given the rates of diabetes reaching ‘epidemic proportions’, we figured it was time to have a better overview of biotech’s progress in the field. With some serious advances having been made in the treatment of the disease, we have to ask – how much further can biotech go in the treatment of diabetes? It is important […]

June 14, 2016 - 9 minutesmins - By Dani Bancroft

innate pharma immunooncology biotech cancer orega sanofi

News and Trends 11 Jan 2016

A French Biotech is Monopolising Immuno-Oncology with Big Euro Deals

Marseille’s Innate Pharma is building an Immuno-Oncology Monopoly, deal by deal. Selling to the French Pharma Giant, Sanofi, this 112 employee biotech has used their Sanofi-income to buy up Lyon-based Orega Biotech‘s checkpoint inhibitor program. Sanofi and Innate Pharma will work together on the generation and evaluation of up to two bispecific NK cell engagers, […]

January 11, 2016 - 3 minutesmins - By Dani Bancroft

hypoxia cancer hpv inthera aglaia oncology

News and Trends 17 Dec 2015

The Assault on Solid Tumors: How ‘Blinding’ Cancer is an Attractive Therapeutic Approach

The Dutch Oncology VC Specialist Aglaia has invested €3.4M in the Swiss Start-Up Inthera Bioscience for their Small molecule platform against solid tumors. Aglaia is a venture capital firm based in Bilthoven (NL) which has 3 funds under their management for specialist investment into Oncology research. Last year they raised over €50M as part of […]

December 17, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 26 Nov 2015

Ablynx Top Trumps: Adding Danish Diabetes Giant Novo Nordisk to its Biotech Deck

Ablynx – the Belgian Nanobody biotech (which uses monoclonal antibodies of Alpacas) has entered a new and exclusive partnership with the Danish Novo Nordisk on a mysterious disease… Ablynx are famously well connected in the biotech industry, with many huge pharmas licensing out their Alpaca-nanobody tech. Partnerships include AbbVie (Immunology), Boehringer Ingelheim, Genzyme (Multiple Sclerosis/CNS), […]

November 26, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 2 Sep 2015

Novo-expansion! US Based Calibrium and MB2 snapped up by Danish Diabetes Giant

Novo Nordisk has acquired two small Indiana based research Biotechs, Calibrium and MB2, as part of its strategy to establish itself in the US as a major Diabetes research giant. Novo Nordisk, a global endocrine research giant hailing from Copenhagen, Denmark, has plans to acquire two smaller, privately held research companies into its conglomeration. Focusing […]

September 2, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 26 Aug 2015

Ouch! Novo Nordisk fails in Phase III

Novo Nordisk joins UCB and gets knocked down by its drug’s final clinical trial. Liraglutide, the already approved adjunct therapy for people with type 2 diabetes won’t reach out to type 1 diabetes. Novo Nordisk can look at a 90-year long history of improving the lives of diabetes patients. However, the phase IIIa trial that […]

August 26, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 17 Aug 2015

Genmab’s Bispecific Antibodies Catch Another Big Fish

Genmab, the Danish company developing the DuoBody technology platform to create and develop bispecific antibody candidates, just signed another licensing agreement with a Big Pharma company. This time, Novo Nordisk has been caught in a potential $502 million (€453m) deal. The DuoBody technology involves three basic steps to generate stable bispecific human IgG1 antibodies. In the first step, […]

August 17, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 15 Aug 2015

The Sky is the Limit: Novo Nordisk continues to rise

The world’s leading insulin supplier, Novo Nordisk, turns in a superb performance in the first six months of 2015. Sales revenues increased, two IIIa trials were successfully completed and two new treatments are now available on the huge diabetes market of the US. We visited Denmark for our last Labiotech tour. We knew Novo was […]

August 15, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 7 Jul 2015

Novo Nordisk abandons Zosano’s drug delivery technology for diabetes treatment

Novo Nordisk cancels its collaboration deal with Zosano Pharma. The diabetes drug semaglutine won’t be delivered with the microneedle patch technology, developed from the latter. Zosano’s patch technology uses thin titanium microprojections to deliver drugs that cannot permeate the outer layer of the skin. According to Zosano, the system was tested on 400 patients in […]

July 7, 2015 - 2 minutesmins - By Philip Hemme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us